Effect of Combined Antiretroviral Therapy on the Levels of Selected Parameters Reflecting Metabolic and Inflammatory Disturbances in HIV-Infected Patients

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Mar 25

PMID 35330038

Authors

Karolina Jurkowska

Beata Szymanska

Brygida Knysz

Agnieszka Piwowar

Affiliations

Soon will be listed here.

Abstract

Subjects infected with human immunodeficiency virus (HIV) treated with combined antiretroviral therapy (cART) show a greater predisposition to metabolic disturbances compared to the general population. The aim of the study was to assess the effect of cART on the level of selected parameters related to carbohydrate and lipid metabolism, cardiovascular diseases and inflammation in the plasma of HIV-infected patients against the uninfected. The levels of irisin (IRS), myostatin (MSTN), peptide YY (PYY), glucagon-like peptide-1 (GLP-1), dipeptidyl peptidase IV (DPP-4), fetuin A (FETU-A), pentraxin 3 (PTX 3), chemokine stromal cell-derived factor 1 (SDF-1), and regulated on activation normal T cell expressed and secreted (RANTES) in the plasma of HIV-infected patients and the control group were measured by immunoassay methods. HIV-infected patients were analyzed in terms of CD4+ T cells and CD8+ T cell count, HIV RNA viral load, and the type of therapeutic regimen containing either protease inhibitors (PIs) or integrase transfer inhibitors (INSTIs). The analysis of HIV-infected patients before and after cART against the control group showed statistically significant differences for the following parameters: IRS ( = 0.02), MSTN ( = 0.03), PYY ( = 0.03), GLP-1 ( = 0.03), PTX3 ( = 0.03), and RANTES ( = 0.02), but no significant differences were found for DPP-4, FETU-A, and SDF-1. Comparing the two applied therapeutic regimens, higher levels of all tested parameters were shown in HIV-infected patients treated with INSTIs compared to HIV-infected patients treated with PIs, but the differences were not statistically significant. The obtained results indicated significant changes in the expression of selected parameters in the course of HIV infection and cART. There is need for further research on the clinical usefulness of the selected parameters and for new information on the pathogenesis of HIV-related comorbidities to be provided. The obtained data may allow for better monitoring of the course of HIV infection and optimization of therapy in order to prevent the development of comorbidities as a result of long-term use of cART.

Citing Articles

Assessment of Metabolic, Inflammatory, and Immunological Disorders Using a New Panel of Plasma Parameters in People Living with HIV Undergoing Antiretroviral Therapy-A Retrospective Study.

Szymanska B, Knysz B, Cieplucha H, Piwowar A J Clin Med. 2024; 13(15).

PMID: 39124846 PMC: 11312710. DOI: 10.3390/jcm13154580.

References

Songok E, Osero B, McKinnon L, Rono M, Apidi W, Matey E . CD26/dipeptidyl peptidase IV (CD26/DPPIV) is highly expressed in peripheral blood of HIV-1 exposed uninfected female sex workers. Virol J. 2010; 7:343. PMC: 3009705. DOI: 10.1186/1743-422X-7-343. View

Srinivasa S, Wong K, Fitch K, Wei J, Petrow E, Cypess A . Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome. Clin Endocrinol (Oxf). 2014; 82(5):678-85. PMC: 4475409. DOI: 10.1111/cen.12582. View

Dube M, Chan E, Lake J, Williams B, Kinslow J, Landay A . A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection. Clin Infect Dis. 2018; 69(7):1165-1172. PMC: 6743814. DOI: 10.1093/cid/ciy1051. View

Samji H, Cescon A, Hogg R, Modur S, Althoff K, Buchacz K . Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8(12):e81355. PMC: 3867319. DOI: 10.1371/journal.pone.0081355. View

Derdeyn C, Costello C, Kilby J, Sfakianos G, Saag M, Kaslow R . Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals. AIDS Res Hum Retroviruses. 1999; 15(12):1063-71. DOI: 10.1089/088922299310359. View

Sesti G, Andreozzi F, Fiorentino T, Mannino G, Sciacqua A, Marini M . High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol. 2014; 51(5):705-13. DOI: 10.1007/s00592-014-0576-0. View

Baczek J, Silkiewicz M, Wojszel Z . Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps. Nutrients. 2020; 12(8). PMC: 7469036. DOI: 10.3390/nu12082401. View

Yeregui E, Vilades C, Domingo P, Ceausu A, Pacheco Y, Veloso S . High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients. EBioMedicine. 2020; 62:103077. PMC: 7653063. DOI: 10.1016/j.ebiom.2020.103077. View

Jang D, Choi B, Kim S . The effects of RANTES/CCR5 promoter polymorphisms on HIV disease progression in HIV-infected Koreans. Int J Immunogenet. 2008; 35(2):101-5. DOI: 10.1111/j.1744-313X.2007.00743.x. View

10.

Ye W, Huang Q, Tang T, Qin G . Diagnostic value of pentraxin 3 in respiratory tract infections: A meta-analysis. Medicine (Baltimore). 2020; 99(14):e19532. PMC: 7220687. DOI: 10.1097/MD.0000000000019532. View

11.

Polyzos S, Anastasilakis A, Efstathiadou Z, Makras P, Perakakis N, Kountouras J . Irisin in metabolic diseases. Endocrine. 2017; 59(2):260-274. DOI: 10.1007/s12020-017-1476-1. View

12.

Ryom L, Cotter A, De Miguel R, Beguelin C, Podlekareva D, Arribas J . 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med. 2020; 21(10):617-624. PMC: 7754379. DOI: 10.1111/hiv.12878. View

13.

Icer M, Yildiran H . Effects of fetuin-A with diverse functions and multiple mechanisms on human health. Clin Biochem. 2020; 88:1-10. DOI: 10.1016/j.clinbiochem.2020.11.004. View

14.

Gonzalez-Cadavid N, TAYLOR W, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S . Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A. 1998; 95(25):14938-43. PMC: 24554. DOI: 10.1073/pnas.95.25.14938. View

15.

Hosono O, Homma T, Kobayashi H, Munakata Y, Nojima Y, Iwamoto A . Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Clin Immunol. 1999; 91(3):283-95. DOI: 10.1006/clim.1999.4711. View

16.

Smith N, Hackett T, Galli A, Flynn C . GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int. 2019; 128:94-105. PMC: 7081944. DOI: 10.1016/j.neuint.2019.04.010. View

17.

Assyov Y, Velikova T, Kamenov Z . Myostatin and carbohydrate disturbances. Endocr Res. 2016; 42(2):102-109. DOI: 10.1080/07435800.2016.1198802. View

18.

Carvalho L, Basso-Vanelli R, Thommazo-Luporini L, Mendes R, Oliveira-Junior M, Vieira R . Myostatin and adipokines: The role of the metabolically unhealthy obese phenotype in muscle function and aerobic capacity in young adults. Cytokine. 2017; 107:118-124. DOI: 10.1016/j.cyto.2017.12.008. View

19.

Lusso P, Vangelista L, Cimbro R, Secchi M, Sironi F, Longhi R . Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J. 2011; 25(4):1230-43. PMC: 3058712. DOI: 10.1096/fj.10-167627. View

20.

Guida C, Ramracheya R . PYY, a Therapeutic Option for Type 2 Diabetes?. Clin Med Insights Endocrinol Diabetes. 2020; 13:1179551419892985. PMC: 6977199. DOI: 10.1177/1179551419892985. View